Is there a need to redefine Parkinson's disease?

Journal of Neural Transmission

Volumn 120, Issue SUPPL. 1, 2013, Pages

  Mahlknecht, Philipp ^a   Poewe, Werner ^a  

^a UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

Biomarker; Early diagnosis; Molecular biomarkers; Neuroimaging; Non motor symptoms; Parkinson's disease (PD); Premotor PD

Indexed keywords

BIOLOGICAL MARKER; MOLECULAR MARKER;

BRAIN BIOPSY; CONSTIPATION; DEPRESSION; GENETIC MARKER; HUMAN; HYPOSMIA; MOTOR DYSFUNCTION; NEUROIMAGING; NEUROPATHOLOGY; NIGRONEOSTRIATAL SYSTEM; PARASOMNIA; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; RISK; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRIATONIGRAL DEGENERATION;

BIOLOGICAL MARKERS; EARLY DIAGNOSIS; HUMANS; NEUROIMAGING; PARKINSON DISEASE;

EID: 84892789293     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-013-1038-5     Document Type: Review

References (101)

1. Abbott RD, Petrovitch H, White LR et al (2001) Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 57:456-462
2. Abbott RD, Ross GW, White LR et al (2005) Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology 65:1442-1446
3. Abbott RD, Ross GW, Petrovitch H et al (2007) Bowel movement frequency in late-life and incidental Lewy bodies. Mov Disord 22:1581-1586
4. Anheim M, Elbaz A, Lesage S et al (2012) Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. Neurology 78:417-420
5. Barone P, Antonini A, Colosimo C et al (2009) The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease. Mov Disord 24:1641-1649
6. Beach TG, Adler CH, Dugger BN et al (2013) Submandibular gland biopsy for the diagnosis of Parkinson disease. J Neuropathol Exp Neurol 72:130-136
7. Behnke S, Schroeder U, Dillmann U et al (2009) Hyperechogenicity of the substantia nigra in healthy controls is related to MRI changes and to neuronal loss as determined by F-Dopa PET. Neuroimage 47:1237-1243
8. Behnke S, Runkel A, Kassar HA et al (2012) Long-term course of substantia nigra hyperechogenicity in Parkinson's disease. Mov Disord 28(4):455-459. doi:10.1002/mds.25193
9. Bennett DA, Beckett LA, Murray AM (1996) Prevalence of Parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 334:71-76
10. Berg D, Poewe W (2012) Can we define "pre-motor" Parkinson's disease? Mov Disord 27:595-596
11. Berg D, Becker G, Zeiler B et al (1999) Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 53:1026-1031
12. Berg D, Roggendorf W, Schroder U et al (2002) Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 59:999-1005
13. Berg D, Godau J, Walter U (2008) Transcranial sonography in movement disorders. Lancet Neurol 7:1044-1055
14. Berg D, Seppi K, Behnke S et al (2011) Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons. Arch Neurol 68:932-937
15. Berg D, Marek K, Ross GW, Poewe W (2012) Defining at-risk populations for Parkinson's disease: lessons from ongoing studies. Mov Disord 27:656-665
16. Berg D, Lang AE, Postuma R et al (2013a) Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol 12(5):514-524
17. Berg D, Behnke S, Seppi K et al (2013b) Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease. Mov Disord 28:216-219
18. Berg D, Godau J, Seppi K et al (2013c) The PRIPS study: screening battery for subjects at risk for Parkinson's disease. Eur J Neurol 20:102-108
19. Besong-Agbo D, Wolf E, Jessen F et al (2013) Naturally occurring asynuclein autoantibody levels are lower in patients with Parkinson disease. Neurology 80:169-175
20. Bezard E, Gross CE, Brotchie JM (2003) Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci 26:215-221
21. Böttner M, Zorenkov D, Hellwig I et al (2012) Expression pattern and localization of alpha-synuclein in the human enteric nervous system. Neurobiol Dis 48:474-480
22. Braak H, Del TK, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197-211
23. Buchman AS, Shulman JM, Nag S et al (2012) Nigral pathology and parkinsonian signs in elders without Parkinson disease. Ann Neurol 71:258-266
24. Chen-Plotkin AS, Hu WT, Siderowf A et al (2010) Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease. Ann Neurol 69:655-663
25. Comella CL (2007) Sleep disorders in Parkinson's disease: an overview. Mov Disord 22(S17):367-373
26. Del TK, Braak H (2012) Lewy pathology and neurodegeneration in premotor Parkinson's disease. Mov Disord 27:597-607
27. Devic I, Hwang H, Edgar JS et al (2011) Salivary alpha-synuclein and DJ-1: potential biomarkers for Parkinson's disease. Brain 134:e178
28. Dickson DW, Fujishiro H, DelleDonne A et al (2008) Evidence that incidental Lewy body disease is pre-symptomatic Parkinson's disease. Acta Neuropathol 115:437-444
29. Dickson DW, Braak H, Duda JE et al (2009) Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 8:1150-1157
30. Erro R, Picillo M, Vitale C et al (2013) Non-motor symptoms in early Parkinson's disease: a 2-year follow-up study on previously untreated patients. J Neurol Neurosurg Psychiatry 84:14-17
31. Fearnley JM, Lees AJ (1991) Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114:2283-2301
32. Foulds PG, Mitchell JD, Parker A (2011) Phosphorylated a-synuclein can be detected in blood plasma and is potentially a useful biomarker for Parkinson's disease. FASEB 25:4127-4137
33. Frauscher B, Nomura T, Duerr S et al (2012) Investigation of autonomic function in idiopathic REM sleep behavior disorder. J Neurol 259:1056-1061
34. Fuente-Fernandez R, Schulzer M, Kuramoto L et al (2011) Agespecific progression of nigrostriatal dysfunction in Parkinson's disease. Ann Neurol 69:803-810
35. Gagnon JF, Postuma RB, Mazza S, Doyon J, Montplaisir J (2006) Rapid-eye-movement sleep behaviour disorder and neurodegenerative diseases. Lancet Neurol 5:424-432
36. Gibb WR, Lees AJ (1988) The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 51:745-752
37. Godau J, Hussl A, Lolekha P, Stoessl AJ, Seppi K et al (2012) Neuroimaging: current role in detecting pre-motor Parkinson's disease. Mov Disord 27:634-643
38. Greffard S, Verny M, Bonnet AM et al (2006) Motor score of the unified Parkinson disease rating scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. Arch Neurol 63:584-588
39. Haehner A, Hummel T, Hummel C, Sommer U, Junghanns S, Reichmann H (2007) Olfactory loss may be a first sign of idiopathic Parkinson's disease. Mov Disord 22:839-842
40. Haehner A, Boesveldt S, Berendse HW (2009) Prevalence of smell loss in Parkinson's disease-a multicenter study. Parkinsonism Relat Disord 15:490-494
41. Hilker R, Schweitzer K, Coburger S et al (2005) Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluoro dopa F 18 activity. Arch Neurol 62:378-382
42. Hong Z, Shi M, Chung KA et al (2010) DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133:713-726
43. International Parkinson Disease Genomics Consortium, Nalls MA, Plagnol V, Hernandez DG et al (2011) Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet 377:641-649
44. Iranzo A, Molinuevo JL, Santamaria J et al (2006) Rapid-eyemovement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol 5:572-577
45. Iranzo A, Valldeoriola F, Lomena F et al (2011) Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol 10:797-805
46. Ishihara L, Brayne C (2006) A systematic review of depression and mental illness preceding Parkinson's disease. Acta Neurol Scand 113:211-220
47. Jankovic J, Poewe W (2012) Therapies in Parkinson's disease. Curr Opin Neurol 25:433-447
48. Kang JH, Caspell C, Coffey C et al (2012) Association between CSF biomarkers and clinical phenotype of early Parkinson's disease in the Parkinson's Progression Marker Initiative (PPMI). Mov Disord 27(S1):34-35
49. Katzenschlager R, Lees AJ (2004) Olfaction and Parkinson's syndromes: its role in differential diagnosis. Curr Opin Neurol 17:417-423
50. Khoo TK, Yarnall AJ, Duncan GW (2013) The spectrum of nonmotor symptoms in early Parkinson disease. Neurology 80:276-281
51. Leentjens AF, Van den Akker M, Metsemakers JF, Lousberg R, Verhey FR (2003) Higher incidence of depression preceding the onset of Parkinson's disease: a register study. Mov Disord 18:414-418
52. Lesko LJ, Atkinson AJ Jr (2001) Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 41:347-366
53. Lill CM, Roehr JT, McQueen MB et al (2012) Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: the PDGene database. PLoS Genet 8:e1002548
54. Louis ED, Bennett DA (2007) Mild Parkinsonian signs: an overview of an emerging concept. Mov Disord 22:1681-1688
55. Maetzler W, Hausdorff JM (2012) Motor signs in the prodromal phase of Parkinson's disease. Mov Disord 27:627-633
56. Maetzler W, Mancini M, Liepelt-Scarfone I et al (2012) Impaired trunk stability in individuals at high risk for Parkinson's disease. PLoS ONE 7:e32240
57. Mahlknecht P, Stockner H, Nocker M et al (2012) A follow-up study of substantia nigra echogenicity in healthy adults. Mov Disord 27:1196-1197
58. Marek K, Innis R, van DC et al (2001) [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 57:2089-2094
59. McKhann GM, Knopman DS, Chertkow H et al (2011) The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7:263-269
60. Miki Y, Tomiyama M, Ueno T, Haga R et al (2010) Clinical availability of skin biopsy in the diagnosis of Parkinson's disease. Neurosci Lett 469:357-359
61. Mirelman A, Gurevich T, Giladi N, Bar-Shira A, Orr-Urtreger A, Hausdorff JM (2011) Gait alterations in healthy carriers of the LRRK2 G2019S mutation. Ann Neurol 69:193-197
62. Mollenhauer B, Zhang J (2012) Biochemical premotor biomarkers for Parkinson's disease. Mov Disord 27:644-650
63. Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Doring F, Trenkwalder C, Schlossmacher MG (2011) Alpha-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with Parkinsonism: a cohort study. Lancet Neurol 10:230-240
64. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ (1998) Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 64:314-319
65. Noyce AJ, Bestwick JP, Silveira-Moriyama L et al (2012) Metaanalysis of early nonmotor features and risk factors for Parkinson disease. Ann Neurol 72:893-901
66. O'Sullivan SS, Williams DR, Gallagher DA, Massey LA, Silveira-Moriyama L, Lees AJ (2008) Nonmotor symptoms as presenting complaints in Parkinson's disease: a clinicopathological study. Mov Disord 23:101-106
67. Parkinson Progression Marker Initiative (2011) The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 95: 629-635
68. Poewe W (2008) Non-motor symptoms in Parkinson's disease. Eur J Neurol 15(S1):14-20
69. Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters EC, Berendse HW (2004) Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 56:173-181
70. Ponsen MM, Stoffers D, Wolters ECh, Booij J, Berendse HW (2010) Olfactory testing combined with dopamine transporter imaging as a method to detect prodromal Parkinson's disease. J Neurol Neurosurg Psychiatry 81:396-399
71. Postuma RB, Lang AE, Massicotte-Marquez J, Montplaisir J (2006) Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology 66:845-851
72. Postuma RB, Gagnon JF, Vendette M, Fantini ML, Massicotte-Marquez J, Montplaisir J (2009) Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 72:1296-1300
73. Postuma RB, Gagnon JF, Vendette M, Desjardins C, Montplaisir J (2011) Olfaction and color vision identify impending neurodegeneration in REM behavior disorder. Ann Neurol 69:811-818
74. Postuma RB, Lang AE, Gagnon JF, Pelletier A, Montplaisir JY (2012a) How does Parkinsonism start? Prodromal Parkinsonism motor changes in idiopathic REM sleep behavior disorder. Brain 135:1860-1870
75. Postuma RB, Aarsland D, Barone P et al (2012b) Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease. Mov Disord 27:617-626
76. Qiang JK, Wong YC, Siderowf A et al (2013) Plasma apolipoprotein A1 as a biomarker for Parkinson's disease. Ann Neurol. doi: 10.1002/ana.23872. [Epub ahead of print]
77. Ray S, Britschgi M, Herbert C et al (2007) Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 13:1359-1362
78. Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF (2008) A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord 23:183-189
79. Ross GW, Petrovitch H, Abbott RD et al (2004) Parkinsonian signs and substantia nigra neuron density in descendents elders without PD. Ann Neurol 56:532-539
80. Ross GW, Abbott RD, Petrovitch H et al (2006) Association of olfactory dysfunction with incidental Lewy bodies. Mov Disord 21:2062-2067
81. Ross GW, Petrovitch H, Abbott RD et al (2008) Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol. 63:167-173
82. Savica R, Carlin JM, Grossardt BR et al (2009) Medical records documentation of constipation preceding Parkinson disease: a case-control study. Neurology 73:1752-1758
83. Schenck CH, Bundlie SR, Ettinger MG, Mahowald MW (1986) Chronic behavioral disorders of human REM sleep: a new category of parasomnia. Sleep 9:293-308
84. Scherfler C, Frauscher B, Schocke M et al (2011) White and gray matter abnormalities in idiopathic rapid eye movement sleep behavior disorder: a diffusion-tensor imaging and voxel-based morphometry study. Ann Neurol 69:400-407
85. Shannon KM, Keshavarzian A, Mutlu E et al (2012a) Alphasynuclein in colonic submucosa in early untreated Parkinson's disease. Mov Disord 27:709-715
86. Shannon KM, Keshavarzian A, Dodiya HB, Jakate S, Kordower JH (2012b) Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov Disord 27:716-719
87. Shi M, Zabetian CP, Hancock AM et al (2010) Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett 480:78-82
88. Shi M, Bradner J, Hancock AM et al (2011) Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 69:570-580
89. Shiba M, Bower JH, Maraganore DM et al (2000) Anxiety disorders and depressive disorders preceding Parkinson's disease: a casecontrol study. Mov Disord 15:669-677
90. Siderowf A, Lang AE (2012) Premotor Parkinson's disease: concepts and definitions. Mov Disord 27:608-616
91. Siderowf A, Jennings D, Eberly S et al (2012) Impaired olfaction and other prodromal features in the Parkinson at-risk syndrome study. Mov Disord 27:406-441
92. Sidransky E, Nalls MA, Aasly JO et al (2009) Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 361:1651-1661
93. Stern MB, Lang A, Poewe W (2012) Toward a redefinition of Parkinson's disease. Mov Disord 27:54-60
94. Stiasny-Kolster K, Doerr Y, Möller JC et al (2005) Combination of 'idiopathic' REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 128:126-137
95. Tokuda T, Qureshi MM, Ardah MT et al (2010) Detection of elevated levels of alpha-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75:1766-1772
96. Unger MM, Belke M, Menzler K et al (2010) Diffusion tensor imaging in idiopathic REM sleep behavior disorder reveals microstructural changes in the brainstem, substantia nigra, olfactory region, and other brain regions. Sleep 33:767-773
97. van Nuenen BF, Weiss MM, Bloem BR et al (2009) Heterozygous carriers of a Parkin or PINK1 mutation share a common functional endophenotype. Neurology 72:1041-1047
98. Vingerhoets FJ, Schulzer M, Calne DB, Snow BJ (1997) Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol 41:58-64
99. Walter U, Hoeppner J, Prudente-Morrissey L, Horowski S, Herpertz SC, Benecke R (2007) Parkinson's disease-like midbrain sonography abnormalities are frequent in depressive disorders. Brain 130:1799-1807
100. Wang Y, Shi M, Chung KA et al (2012) Phosphorylated alphasynuclein in Parkinson's disease. Sci Transl Med 4:121
101. Yanamandra K, Gruden MA, Casaite V, Meskys R, Forsgren L, Morozova-Roche LA (2011) Alpha-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients. PLoS ONE 6:e18513